Marketing authorisation restricts use to postmenopausal women without symptomatic visceral disease after recurrence or progression following a non-steroidal aromatase inhibitor.
NICE TA295 does not recommend the use of everolimus in combination with exemestane for treating advanced HER2-negative hormone-receptor-positive breast cancer after endocrine therapy. NICE is however currently re-reviewing this indication for everolimus under a new technology appraisal.